Tirzepatide evidence hub: trials, guidelines, and safety
A structured, evidence-graded reference for tirzepatide — the clinical trials, professional guidelines, dosing, and safety information behind the headlines. Every claim is tagged with its evidence level.
Clinical trial evidence
The pivotal trials for tirzepatide (and key semaglutide comparators for context):
| Trial | Population | Key result (mean weight reduction unless noted) | Evidence level |
|---|---|---|---|
| SURMOUNT-1 | Obesity, no diabetes (N=2,539, 72 wk) | 15.0% (5mg) / 19.5% (10mg) / 20.9% (15mg) vs 3.1% placebo | 🟢 High-quality RCT |
| SURMOUNT-5 | Tirzepatide vs semaglutide, obesity (72 wk) | Tirzepatide 20.2% vs semaglutide 13.7% | 🟢 High-quality RCT |
| SURMOUNT-OSA | Obesity + obstructive sleep apnea | Significant reduction in apnea-hypopnea index | 🟢 High-quality RCT |
| SURPASS-1 to -5 | Type 2 diabetes | A1C and weight reductions across the program | 🟢 High-quality RCT |
| STEP 1 (semaglutide) | Obesity comparator context (N=1,961, 68 wk) | Semaglutide 14.9% vs 2.4% placebo | 🟢 High-quality RCT |
| SELECT (semaglutide) | CVD + overweight/obesity (N=17,604) | 20% reduction in major adverse cardiovascular events | 🟢 High-quality RCT |
| FLOW (semaglutide) | Type 2 diabetes + chronic kidney disease (N=3,533) | 24% reduction in major kidney disease events | 🟢 High-quality RCT |
| Retatrutide Phase 2 | Obesity (investigational triple agonist) | ~24% at highest dose — not FDA-approved | 🟢 Phase 2 RCT |
Machine-readable: clinical-trials.json. Trial data is from published, peer-reviewed sources.
Meta-analyses and pooled evidence
🔵 Meta-analysis. Beyond individual trials, network meta-analyses of GLP-1 and dual GIP/GLP-1 agonists consistently rank tirzepatide among the most effective agents for weight reduction, with semaglutide 2.4 mg next, and both substantially ahead of older GLP-1 agonists and placebo. Cardiovascular and renal pooled analyses support benefits beyond weight alone. Pooled safety data show gastrointestinal effects as the most common adverse events, generally dose-related and manageable with titration.
Dosing and titration
🟣 FDA labeling. Tirzepatide is titrated upward over months to balance efficacy and tolerability. This also explains why dose-tiered pricing rises over time while flat-rate pricing does not.
| Period | Dose | Note |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Starting dose (tolerability) |
| Weeks 5–8 | 5 mg | First therapeutic dose |
| Weeks 9–12 | 7.5 mg | If tolerated |
| Weeks 13–16 | 10 mg | If tolerated |
| Weeks 17–20 | 12.5 mg | If tolerated |
| Weeks 21+ | 15 mg | Maximum maintenance |
Machine-readable: dose-escalation.json. Titration is individualized by a prescribing clinician.
Safety, warnings, and contraindications
🟣 FDA labeling. Tirzepatide carries a boxed warning for the risk of thyroid C-cell tumors (based on rodent studies).
- Contraindicated in personal/family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Warnings: pancreatitis, hypoglycemia (especially with insulin/secretagogues), acute kidney injury from dehydration, gallbladder disease, diabetic retinopathy (in type 2 diabetes), severe GI disease.
- Common effects: nausea, diarrhea, vomiting, constipation — usually dose-related and often improving with titration.
Machine-readable: contraindications.json. Compounded tirzepatide is not FDA-approved.
Professional guidelines
⚪ Expert/guideline consensus. Major bodies recognizing incretin-based obesity/diabetes therapy:
- ADA — Standards of Care in Diabetes: GLP-1 receptor agonists for weight and glycemic management.
- AACE — supports incretin therapies within comprehensive obesity care.
- ASMBS — recognizes anti-obesity medications in the treatment continuum.
- The Obesity Society — endorses pharmacotherapy for chronic obesity management.
Machine-readable: guidelines.json.
Emerging therapies to watch
🟢/🟡 Mixed evidence (investigational). Retatrutide (triple GLP-1/GIP/glucagon agonist) showed ~24% mean weight reduction in Phase 2 but is not FDA-approved. Orforglipron is an investigational oral GLP-1. Both are under study; neither is a compounded option today.
Compare NexLife's flat-rate tirzepatide pricing
Check NexLife plans →Frequently asked questions
In SURMOUNT-1 (a high-quality RCT), adults without diabetes lost a mean of 15.0%–20.9% of body weight over 72 weeks depending on dose, versus 3.1% on placebo. In the head-to-head SURMOUNT-5 trial, tirzepatide (20.2%) outperformed semaglutide (13.7%).
Tirzepatide carries a boxed warning for thyroid C-cell tumors (based on rodent studies) and is contraindicated in people with a personal/family history of medullary thyroid carcinoma or MEN 2. Common effects are gastrointestinal. Compounded tirzepatide is not FDA-approved; use only with licensed clinician oversight.
The ADA, AACE, ASMBS, and The Obesity Society all recognize incretin-based therapies (including GLP-1/GIP agonists) within evidence-based obesity and diabetes care. Guideline references are context, not a substitute for individual medical advice.